Trial · NCT01884675
Results by group138
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 138
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Six Minutes Walking Distance (6MWD) at Week 16 | Placebo | Week 4, n=15, 17 | 5.00 | Inter-Quartile Range -1.50 to 16.50 | Meters |
| Change From Baseline in Six Minutes Walking Distance (6MWD) at Week 16 | Ambrisentan 5mg | Week 4, n=15, 17 | 14.00 | Inter-Quartile Range 1.00 to 42.50 | Meters |
| Change From Baseline in Six Minutes Walking Distance (6MWD) at Week 16 | Placebo | Week 8, n=14, 16 | 7.50 | Inter-Quartile Range -14.50 to 22.50 | Meters |
| Change From Baseline in Six Minutes Walking Distance (6MWD) at Week 16 | Ambrisentan 5mg | Week 8, n=14, 16 | 26.25 | Inter-Quartile Range 3.25 to 61.25 | Meters |
| Change From Baseline in Six Minutes Walking Distance (6MWD) at Week 16 | Placebo | Week 12, n=13, 15 | 5.50 | Inter-Quartile Range -23.00 to 39.50 | Meters |
| Change From Baseline in Six Minutes Walking Distance (6MWD) at Week 16 | Ambrisentan 5mg | Week 12, n=13, 15 | 20.50 | Inter-Quartile Range 4.00 to 68.00 | Meters |
| Change From Baseline in Six Minutes Walking Distance (6MWD) at Week 16 | Placebo | Week 16, n=13, 15 | -10.00 | Inter-Quartile Range -32.50 to 20.00 | Meters |
| Change From Baseline in Six Minutes Walking Distance (6MWD) at Week 16 | Ambrisentan 5mg | Week 16, n=13, 15 | 25.00 | Inter-Quartile Range 12.00 to 49.00 | Meters |
| Change From Baseline in Six Minutes Walking Distance (6MWD) at Week 16 | Placebo | Early Withdrawal, n=3, 2 | 7.50 | Inter-Quartile Range -46.50 to 43.50 | Meters |
| Change From Baseline in Six Minutes Walking Distance (6MWD) at Week 16 | Ambrisentan 5mg | Early Withdrawal, n=3, 2 | 41.25 | Inter-Quartile Range 0.00 to 82.50 | Meters |
| Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 16 | Placebo | -103.0 | Inter-Quartile Range -122.0 to -88.0 | Dynes*second/centimeter^5 | |
| Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 16 | Ambrisentan 5mg | -130.0 | Inter-Quartile Range -502.0 to -78.0 | Dynes*second/centimeter^5 | |
| Change From Baseline in WHO Functional Class (FC) at Weeks 4, 8, 12 and 16/Early Withdrawal | Placebo | Week 4, n=15, 17 | 0.0 | Inter-Quartile Range 0.0 to 0.0 | Scores on a scale |
| Change From Baseline in WHO Functional Class (FC) at Weeks 4, 8, 12 and 16/Early Withdrawal | Ambrisentan 5mg | Week 4, n=15, 17 | 0.0 | Inter-Quartile Range 0.0 to 0.0 | Scores on a scale |
| Change From Baseline in WHO Functional Class (FC) at Weeks 4, 8, 12 and 16/Early Withdrawal | Placebo | Week 8, n=14, 16 | 0.0 | Inter-Quartile Range 0.0 to 0.0 | Scores on a scale |
| Change From Baseline in WHO Functional Class (FC) at Weeks 4, 8, 12 and 16/Early Withdrawal | Ambrisentan 5mg | Week 8, n=14, 16 | 0.0 | Inter-Quartile Range 0.0 to 0.0 | Scores on a scale |
| Change From Baseline in WHO Functional Class (FC) at Weeks 4, 8, 12 and 16/Early Withdrawal | Placebo | Week 12, n=13, 15 | 0.0 | Inter-Quartile Range 0.0 to 0.0 | Scores on a scale |
| Change From Baseline in WHO Functional Class (FC) at Weeks 4, 8, 12 and 16/Early Withdrawal | Ambrisentan 5mg | Week 12, n=13, 15 | 0.0 | Inter-Quartile Range -1.0 to 0.0 | Scores on a scale |
| Change From Baseline in WHO Functional Class (FC) at Weeks 4, 8, 12 and 16/Early Withdrawal | Placebo | Week 16, n=13, 15 | 0.0 | Inter-Quartile Range 0.0 to 0.0 | Scores on a scale |
| Change From Baseline in WHO Functional Class (FC) at Weeks 4, 8, 12 and 16/Early Withdrawal | Ambrisentan 5mg | Week 16, n=13, 15 | 0.0 | Inter-Quartile Range -1.0 to 0.0 | Scores on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01884675/results